Charles Schwab Investment Management Inc Acelrx Pharmaceuticals Inc Transaction History

Charles Schwab Investment Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.18 - $0.29 $22,975 - $37,015	127,639 New	127,639 $32,000
Q1 2022 May 13, 2022	SELL	$0.28 - $0.61 $13,596 - $29,621	-48,560 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.03 - $1.7 $220,048 - $363,186	-213,639 Reduced 81.48%	48,560 $68,000
Q1 2021 May 17, 2021	BUY	$1.25 - $2.77 $74,662 - $165,452	59,730 Added 29.5%	262,199 $446,000
Q4 2020 Feb 16, 2021	BUY	$1.18 - $1.98 $17,770 - $29,818	15,060 Added 8.04%	202,469 $252,000
Q3 2020 Nov 13, 2020	SELL	$1.01 - $1.81 $18,389 - $32,954	-18,207 Reduced 8.85%	187,409 $267,000
Q2 2020 Aug 14, 2020	BUY	$1.03 - $1.69 $14,556 - $23,884	14,133 Added 7.38%	205,616 $249,000
Q2 2019 Aug 09, 2019	BUY	$2.1 - $3.93 $342,394 - $640,766	163,045 Added 573.33%	191,483 $485,000
Q1 2019 May 14, 2019	BUY	$2.35 - $3.83 $32,284 - $52,616	13,738 Added 93.46%	28,438 $99,000
Q3 2018 Nov 13, 2018	BUY	$2.6 - $4.6 $38,220 - $67,620	14,700 New	14,700 $57,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.